Introduction: 135La has favorable nuclear and chemical properties for Auger-based targeted internal radiotherapy. Here we present detailed investigations of the production, emissions, imaging characteristics, and dosimetry related to 135La therapy. Methods and Results: 135La was produced by 16.5 MeV proton irradiation of metallic natBa on a medical cyclotron, and was isolated and purified by trap-and-release on weak cation-exchange resin. The average production rate was 407 ± 19 MBq/µA (saturation activity, n = 3), and the radionuclidic purity was 98% at 20 h post irradiation. Chemical separation recovered > 98 % of the 135La with an effective molar activity of 70 ±20 GBq/µmol. To better assess cellular and organ dosimetry of this nuclide, we have recalculated the X-ray and Auger emission spectra using a Monte Carlo model accounting for effects of multiple vacancies during the Auger cascade. The generated Auger spectrum was used to recalculate cellular S-factors. Conclusion: 135La was produced with high specific activity, reactivity, radionuclidic purity, and yield. The emission spectrum and the dosimetry are favorable for internal radionuclide therapy. .
- Auger therapy
- isotope production
- radionuclide therapy
Fonslet, J., Lee, B. Q., Tran, T. A., Siragusa, M., Jensen, M., Kibedi, T., ... Severin, G. (2018). 135La as an auger-electron emitter for targeted internal radiotherapy. Physics in Medicine and Biology, 63(1), . https://doi.org/10.1088/1361-6560/aa9b44